Quick tour through Beserab CREATE, CHOIR, TREAT. Meta analysis #NKFClinicals
What effects the trials had on ESA use: Gold is Hgb, Grey is weekly EPO dose. TREAT caused overnight change in dosing.
LOUDER FOR THE PEOPLE IN THE BACK OF THE ROOM, “No significant association was found between improvements in Hgb levels with treatment and any of the 5-dimensions of quality of life.” #NKFClinicals
Now on to the Pivotal Trial of IV iron. N=2141 she reports is as no difference, but I thought after the correction there was a reduction in events? #oops#NKFClinicals
Next up is Kirsten Johansen from U of Minnesota on Emerging therapies for CKD-related anemia. She starts with a question. This is a nightmare question and will not be participating. She mocks the audience for answering wrong. #NKFClinicals
Big list of trials so you can keep the trials straight #NKFClinicals
After showing data that the HIF stabilizers raise the hemoglobin she gets to the MACE data. First up Roxa. (Emoji, my addition) #NKFClinicals
Brad is a fill in for Samir Parik
He has massive COI all over the place. Every drug. Every company. #NKFClinicals
Starts out with a case. Cr up from 0.6 to 1.2. 3500 mg of protein. Biopsy is WHO 4 and 5. She does not respond to MMF and steroids. Then does not respond to CYT. What to do?
Beware of getting on the roulette wheel of immunosuppression
We target proteinuria because reducing proteinuria is associated with good outcomes. Turns out, people whose kidneys heal have better outcomes. #NKFClinicals